Nicholas Cosford

last updated 1/31/2018

Nicholas Dp Cosford

Professor at Sanford-Burnham Medical Research Institute

Location:
10901 North Torrey Pines Road, La Jolla, California, United States
HQ Phone:
(858) 646-3100

General Information

Experience

Associate Professor - Burnham Institute

Co-founder and Head of Drug Discovery - Camino Pharma , LLC

Senior Investigator - Merck & Co. , Inc.

Education

Ph. D.Burnham Institute for Medical Research

Affiliations

Scientific Advisory Board Member - Plex Pharmaceuticals Inc

Scientific Advisory Board Member - CalAsia Pharmaceuticals Inc

Recent News  

Plex

Nicholas DP Cosford, PhD
Dr. Cosford is Professor at Sanford Burnham Medical Research Institute, La Jolla, California. His research is involved in investigating the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. One aspect of his research emphasizes the use of medicinal chemistry and chemical biology approaches to probe intracellular pathways that regulate cell survival and cell growth. Another area of active research is the development of synthetic chemistry methodology using microfluidic technology for the rapid synthesis of biologically active small molecules. Therapeutically, his group is primarily focused on the discovery and optimization of compounds that have the potential to treat cancer, CNS diseases and infectious diseases. He has more than 20 years of experience leading small-molecule drug discovery projects in the pharmaceutical industry. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small- molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical for PD; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to Phase I clinical (ongoing); and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate; design, synthesis and optimization of an Akt allosteric inhibitor preclinical candidate. To date, he has published more than 55 peer reviewed scientific publications, has more than 30 issued patents, and more than 30 additional patent applications pending. In 2006 he received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.

Read More
Graduate School Faculty

Nicholas Cosford, Ph.D.
Associate Director of Translational Research, NCI-Designated Cancer Center Professor, NCI-Designated Cancer Center Dr. Cosford's laboratory uses medicinal chemistry, chemical biology, rational drug design and microfluidic approaches to develop small-molecule modulators of cell death, survival and growth signaling pathways, for use as novel therapeutic agents to treat cancer, neurodegenerative and psychiatric disorders, and orphan diseases.

Read More
http://www.calasiapharma.com/web/page.php?cid=3&pid=1

Prof. Nicholas Cosford, PhD
Dr. Cosford is Professor at Sanford Burnham Medical Research Institute, La Jolla, California. His research is involved in investigating the interactions of small molecule compounds with therapeutically important proteins and cellular signaling pathways. One aspect of his research emphasizes the use of medicinal chemistry and chemical biology approaches to probe intracellular pathways that regulate cell survival and cell growth. Another area of active research is the development of synthetic chemistry methodology using microfluidic technology for the rapid synthesis of biologically active small molecules. Therapeutically, his group is primarily focused on the discovery and optimization of compounds that have the potential to treat cancer, CNS diseases and infectious diseases. He has more than 20 years of experience leading small-molecule drug discovery projects in the pharmaceutical industry. At Sibia Neurosciences and at Merck Research Laboratories he directed multidisciplinary research teams focused on small-molecule hit-to-lead optimization and was responsible for moving several lead compounds through to the clinical phase. Examples include taking a nicotinic receptor agonist (Altinicline, SIB-1508Y) from initiation of research through to Phase II clinical for PD; taking mGluR5 negative allosteric modulators from HTS hits through in vivo proof-of-concept to Phase I clinical (ongoing); and design, synthesis and optimization of an mGluR5 PET tracer clinical candidate; design, synthesis and optimization of an Akt allosteric inhibitor preclinical candidate. To date, he has published more than 55 peer reviewed scientific publications, has more than 30 issued patents, and more than 30 additional patent applications pending. In 2006 he received the FRAXA Research Foundation Award for Outstanding Contributions to Fragile X Research.

Read More

Browse ZoomInfo’s Directories